We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current MEDXF market cap is 29.11M. The company's latest EPS is USD 0.0499 and P/E is 32.26.
| Year End March 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 33.86M | 74.36M | 79.66M | 76.7M | 108.1M |
| Operating Income | -1.03M | -4.87M | -294k | -14.91M | 7.88M |
| Net Income | -6.52M | -6.24M | -28.26M | -2.88M | 1.22M |
| Year End March 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 113.5M | 174.17M | 148.51M | 139.23M | 161.33M |
| Total Liabilities | 76.29M | 139.74M | 130.5M | 121.43M | 138.88M |
| Total Equity | 37.22M | 34.44M | 18.02M | 17.79M | 22.45M |
| Year End March 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -2.59M | -2.3M | 5.04M | -1.18M | -1.44M |
| Investing | -23.12M | -40.52M | -11.7M | -8.2M | -1.72M |
| Financing | 51.24M | 20.71M | 18.68M | 663k | 6.41M |
| Market Cap | 29.11M |
| Price to Earnings Ratio | 32.26 |
| Price to Sales Ratio | 0.36 |
| Price to Cash Ratio | 3.01 |
| Price to Book Ratio | 1.75 |
| Dividend Yield | - |
| Shares Outstanding | 24.46M |
| Average Volume (1 week) | 10.18k |
| Average Volume (1 Month) | 12.95k |
| 52 Week Change | 23.74% |
| 52 Week High | 2.562 |
| 52 Week Low | 0.8376 |
| Spread (Intraday) | 0.39 (27.66%) |
| Company Name | Medexus Pharmaceuticals Inc (QX) |
| Address |
35 nixon road, unit 1 bolton L7E 1K1 |
| Website | https://www.medexus.com |
| Industry | blank checks (6770) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
